From yeast to patient neurons and back again: powerful new discovery platform.
Identifieur interne : 000576 ( Main/Exploration ); précédent : 000575; suivant : 000577From yeast to patient neurons and back again: powerful new discovery platform.
Auteurs : Daniel F. Tardiff [États-Unis] ; Vikram Khurana ; Chee Yeun Chung ; Susan LindquistSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , genetics : alpha-Synuclein.
- genetics : Movement Disorders, Yeasts.
- metabolism : Neurons, Yeasts, alpha-Synuclein.
- pathology : Movement Disorders.
- Animals, Humans, Translational Medical Research.
Abstract
No disease-modifying therapies are available for synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA). The lack of therapies has been impeded by a paucity of validated drug targets and problematic cell-based model systems. New approaches are therefore needed to identify genes and compounds that directly target the underlying cellular pathologies elicited by the pathological protein, α-synuclein (α-syn). This small, lipid-binding protein impinges on evolutionarily conserved processes such as vesicle trafficking and mitochondrial function. For decades, the genetically tractable, single-cell eukaryote, budding yeast, has been used to study nearly all aspects of cell biology. More recently, yeast has revealed key insights into the underlying cellular pathologies caused by α-syn. The robust cellular toxicity caused by α-syn expression facilitates unbiased high-throughput small-molecule screening. Critically, one must validate the discoveries made in yeast in disease-relevant neuronal models. Here, we describe two recent reports that together establish yeast-to-human discovery platforms for synucleinopathies. In this exemplar, genes and small molecules identified in yeast were validated in patient-derived neurons that present the same cellular phenotypes initially discovered in yeast. On validation, we returned to yeast, where unparalleled genetic approaches facilitated the elucidation of a small molecule's mode of action. This approach enabled the identification and neuronal validation of a previously unknown "druggable" node that interfaces with the underlying, precipitating pathologies caused by α-syn. Such platforms can provide sorely needed leads and fresh ideas for disease-modifying therapy for these devastating diseases.
DOI: 10.1002/mds.25989
PubMed: 25131316
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000422
- to stream PubMed, to step Curation: 000422
- to stream PubMed, to step Checkpoint: 000587
- to stream Ncbi, to step Merge: 004081
- to stream Ncbi, to step Curation: 004081
- to stream Ncbi, to step Checkpoint: 004081
- to stream Main, to step Merge: 000576
- to stream Main, to step Curation: 000576
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">From yeast to patient neurons and back again: powerful new discovery platform.</title>
<author><name sortKey="Tardiff, Daniel F" sort="Tardiff, Daniel F" uniqKey="Tardiff D" first="Daniel F" last="Tardiff">Daniel F. Tardiff</name>
<affiliation wicri:level="2"><nlm:affiliation>Whitehead Institute for Biomedical Research (WIBR), Cambridge, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Whitehead Institute for Biomedical Research (WIBR), Cambridge, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khurana, Vikram" sort="Khurana, Vikram" uniqKey="Khurana V" first="Vikram" last="Khurana">Vikram Khurana</name>
</author>
<author><name sortKey="Chung, Chee Yeun" sort="Chung, Chee Yeun" uniqKey="Chung C" first="Chee Yeun" last="Chung">Chee Yeun Chung</name>
</author>
<author><name sortKey="Lindquist, Susan" sort="Lindquist, Susan" uniqKey="Lindquist S" first="Susan" last="Lindquist">Susan Lindquist</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25131316</idno>
<idno type="pmid">25131316</idno>
<idno type="doi">10.1002/mds.25989</idno>
<idno type="wicri:Area/PubMed/Corpus">000422</idno>
<idno type="wicri:Area/PubMed/Curation">000422</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000587</idno>
<idno type="wicri:Area/Ncbi/Merge">004081</idno>
<idno type="wicri:Area/Ncbi/Curation">004081</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004081</idno>
<idno type="wicri:Area/Main/Merge">000576</idno>
<idno type="wicri:Area/Main/Curation">000576</idno>
<idno type="wicri:Area/Main/Exploration">000576</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">From yeast to patient neurons and back again: powerful new discovery platform.</title>
<author><name sortKey="Tardiff, Daniel F" sort="Tardiff, Daniel F" uniqKey="Tardiff D" first="Daniel F" last="Tardiff">Daniel F. Tardiff</name>
<affiliation wicri:level="2"><nlm:affiliation>Whitehead Institute for Biomedical Research (WIBR), Cambridge, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Whitehead Institute for Biomedical Research (WIBR), Cambridge, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khurana, Vikram" sort="Khurana, Vikram" uniqKey="Khurana V" first="Vikram" last="Khurana">Vikram Khurana</name>
</author>
<author><name sortKey="Chung, Chee Yeun" sort="Chung, Chee Yeun" uniqKey="Chung C" first="Chee Yeun" last="Chung">Chee Yeun Chung</name>
</author>
<author><name sortKey="Lindquist, Susan" sort="Lindquist, Susan" uniqKey="Lindquist S" first="Susan" last="Lindquist">Susan Lindquist</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Movement Disorders (genetics)</term>
<term>Movement Disorders (pathology)</term>
<term>Neurons (metabolism)</term>
<term>Translational Medical Research</term>
<term>Yeasts (genetics)</term>
<term>Yeasts (metabolism)</term>
<term>alpha-Synuclein (genetics)</term>
<term>alpha-Synuclein (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>alpha-Synuclein</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Movement Disorders</term>
<term>Yeasts</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neurons</term>
<term>Yeasts</term>
<term>alpha-Synuclein</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Translational Medical Research</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">No disease-modifying therapies are available for synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA). The lack of therapies has been impeded by a paucity of validated drug targets and problematic cell-based model systems. New approaches are therefore needed to identify genes and compounds that directly target the underlying cellular pathologies elicited by the pathological protein, α-synuclein (α-syn). This small, lipid-binding protein impinges on evolutionarily conserved processes such as vesicle trafficking and mitochondrial function. For decades, the genetically tractable, single-cell eukaryote, budding yeast, has been used to study nearly all aspects of cell biology. More recently, yeast has revealed key insights into the underlying cellular pathologies caused by α-syn. The robust cellular toxicity caused by α-syn expression facilitates unbiased high-throughput small-molecule screening. Critically, one must validate the discoveries made in yeast in disease-relevant neuronal models. Here, we describe two recent reports that together establish yeast-to-human discovery platforms for synucleinopathies. In this exemplar, genes and small molecules identified in yeast were validated in patient-derived neurons that present the same cellular phenotypes initially discovered in yeast. On validation, we returned to yeast, where unparalleled genetic approaches facilitated the elucidation of a small molecule's mode of action. This approach enabled the identification and neuronal validation of a previously unknown "druggable" node that interfaces with the underlying, precipitating pathologies caused by α-syn. Such platforms can provide sorely needed leads and fresh ideas for disease-modifying therapy for these devastating diseases.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
</list>
<tree><noCountry><name sortKey="Chung, Chee Yeun" sort="Chung, Chee Yeun" uniqKey="Chung C" first="Chee Yeun" last="Chung">Chee Yeun Chung</name>
<name sortKey="Khurana, Vikram" sort="Khurana, Vikram" uniqKey="Khurana V" first="Vikram" last="Khurana">Vikram Khurana</name>
<name sortKey="Lindquist, Susan" sort="Lindquist, Susan" uniqKey="Lindquist S" first="Susan" last="Lindquist">Susan Lindquist</name>
</noCountry>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Tardiff, Daniel F" sort="Tardiff, Daniel F" uniqKey="Tardiff D" first="Daniel F" last="Tardiff">Daniel F. Tardiff</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000576 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000576 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:25131316 |texte= From yeast to patient neurons and back again: powerful new discovery platform. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25131316" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |